Telix paid $165 billion upfront primarily to secure ITM’s lead radioligand candidate ITM-11, which was recently rejected by ...

Iambic Therapeutics is maintaining the momentum generated by its recent megaround and Big Pharma partnerships by gearing up ...

An investigational drug for the autoimmune condition Sjögren's disease has scored a phase 3 win for Amgen, marking a positive ...

Barzolvolimab is a monoclonal antibody that binds to the receptor tyrosine kinase KIT and inhibits its activity. KIT is expressed in mast cells, the primary drivers of the inflammatory response in CSU ...

A phase 3 study of Otsuka and Ionis Pharmaceuticals’ amyotrophic lateral sclerosis (ALS) drug candidate has hit its primary endpoint, positioning the partners to talk to regulators about expedited ...

Vertex has reported positive phase 2b data for its kidney disease prospect inaxaplin, boosting its efforts to expand beyond the population targeted in a pivotal trial. The phase 2 ...

Lexeo Therapeutics has agreed to acquire Mantle Therapeutics via an upfront payment of $8.3 million, aiming to expand its Friedreich’s ataxia (FA) portfolio while locking in three strategic ...

Boehringer Ingelheim and AI drug discovery company Envisagenics have agreed to a potential $1 billion multi-year pact that will task Boehringer with validating tumor-specific targets.  | Boehringer ...

Eli Lilly-backed TRex Bio and hypertension-focused Retension Pharmaceuticals are the latest biotechs to set out plans to go ...

Beacon Therapeutics has found the light in a rare vision loss disease that has left larger companies in the dark. | Beacon Therapeutics has found the light in a rare vision loss disease that has left ...

President Donald Trump is attempting to seize further control of funding decisions made by the National Institutes of Health. | President Donald Trump is attempting to seize further control of funding ...

Following Takeda’s historic approval of the first orexin agonist with its narcolepsy treatment Orzeyful, Alkermes has followed up with pioneering data that looks to take the hyped drug class out of ...